Laboratory of Bacterial Pathogenesis and Immunology, The Rockefeller University, New York, New York, United States of America.
PLoS One. 2013 Apr 10;8(4):e60754. doi: 10.1371/journal.pone.0060754. Print 2013.
We identified an essential cell wall biosynthetic enzyme in Bacillus anthracis and an inhibitor thereof to which the organism did not spontaneously evolve measurable resistance. This work is based on the exquisite binding specificity of bacteriophage-encoded cell wall-hydrolytic lysins, which have evolved to recognize critical receptors within the bacterial cell wall. Focusing on the B. anthracis-specific PlyG lysin, we first identified its unique cell wall receptor and cognate biosynthetic pathway. Within this pathway, one biosynthetic enzyme, 2-epimerase, was required for both PlyG receptor expression and bacterial growth. The 2-epimerase was used to design a small-molecule inhibitor, epimerox. Epimerox prevented growth of several Gram-positive pathogens and rescued mice challenged with lethal doses of B. anthracis. Importantly, resistance to epimerox was not detected (<10(-11) frequency) in B. anthracis and S. aureus. These results describe the use of phage lysins to identify promising lead molecules with reduced resistance potential for antimicrobial development.
我们鉴定了炭疽杆菌中一种必需的细胞壁生物合成酶及其抑制剂,该生物体未自发进化出可测量的耐药性。这项工作基于噬菌体编码的细胞壁水解溶菌酶的精细结合特异性,这些溶菌酶已进化为识别细菌细胞壁内的关键受体。我们专注于炭疽杆菌特异性 PlyG 溶菌酶,首先鉴定了其独特的细胞壁受体和同源生物合成途径。在该途径中,一种生物合成酶 2-差向异构酶,既需要 PlyG 受体的表达,也需要细菌的生长。我们利用 2-差向异构酶设计了一种小分子抑制剂 epimerox。epimerox 可阻止几种革兰氏阳性病原体的生长,并可挽救接受致死剂量炭疽杆菌攻击的小鼠。重要的是,在炭疽杆菌和金黄色葡萄球菌中未检测到对 epimerox 的耐药性(<10(-11)频率)。这些结果描述了利用噬菌体溶菌酶来鉴定具有降低的抗药性潜力的有前途的先导分子,用于抗菌药物的开发。